Effect on Cognitive Function of a Treatment With Aripiprazole

Phase 4

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Aripiprazole

• Registration Number: NCT00329810
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03
• Study First Submitted: 2005-09-12
• Primary Completion: 2006-03
• Study Completion: 2006-03
• Study First Submitted QC: 2006-05-24
• Study First Posted: 2006-05-25
• Status Verified: 2012-02
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Diagnosis of Schizophrenia
• score of 2-6 in the CGI-S scale at basline
• ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment

Exclusion Criteria

• women of child bearing potential
• women pregnant or breast feeding
• patients with a score of 0,-1 or 7
• substance use

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Switch	Aripiprazole	-

Primary Outcome Measures

Name	Time	Method
Clinical Global Impression scale at endpoint

Secondary Outcome Measures

Name	Time	Method
Change in Clinical Global Impression scale and cognition scales at endpoint